Results 71 to 80 of about 1,591,450 (336)

Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study [PDF]

, 2019
Background Eribulin mesylate (E) is indicated for metastatic breast cancer patients previously treated with anthracycline and taxane. We argued that E could also benefit patients eligible for neoadjuvant chemotherapy. Methods Patients with primary triple
Apolone G., Bianchi G. V., Cazzaniga M. E., Colombo M. P., Cosimo S. D., Crippa F., de Braud F., De Santis M. C., Folli S., Generali D., Gulino A., Mariani L., Moretti A., Nicola M. D., Paolini B., Scaperrotta G., Torri V., Tripodo C., Verde N. L.   +18 more
core   +2 more sources

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

Breast Cancer Research and Treatment, 2017
PurposeAgents targeting programmed death receptor 1 (PD-1) or its ligand (PD-L1) have shown antitumor activity in the treatment of metastatic breast cancer (MBC).
L. Dirix, I. Takács, G. Jerusalem, P. Nikolinakos, H. Arkenau, A. Forero-Torres, R. Boccia, M. Lippman, R. Somer, M. Šmakal, L. Emens, B. Hrinczenko, W. Edenfield, J. Gurtler, A. von Heydebreck, H. Grote, K. Chin, E. Hamilton   +17 more
semanticscholar   +1 more source

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

Molecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts, Senada Koljenović, Elise Daems, Karolien De Wael, Marc Peeters, Léon C. van Kempen, Greetje Vanhoutte, Karen Zwaenepoel, Timon Vandamme   +8 more
wiley   +1 more source

CD1d-expressing breast cancer cells modulate NKT cell-mediated antitumor immunity in a murine model of breast cancer metastasis. [PDF]

PLoS ONE, 2011
Tumor tolerance and immune suppression remain formidable obstacles to the efficacy of immunotherapies that harness the immune system to eradicate breast cancer.
Laura M Hix, Yihui H Shi, Randy R Brutkiewicz, Paul L Stein, Chyung-Ru Wang, Ming Zhang   +5 more
doaj   +1 more source

Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancer. [PDF]

, 2013
While overall survival (OS) has historically been the primary endpoint for clinical trials in oncology, progression-free survival (PFS) has gained acceptance as a valuable surrogate endpoint.
Crosby, Ross D, Hurvitz, Sara A, Lalla, Deepa, Mathias, Susan D   +3 more
core   +2 more sources

Adenosine‐to‐inosine editing of miR‐200b‐3p is associated with the progression of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
A‐to‐I editing of miRNAs, particularly miR‐200b‐3p, contributes to HGSOC progression by enhancing cancer cell proliferation, migration and 3D growth. The edited form is linked to poorer patient survival and the identification of novel molecular targets.
Magdalena Niemira, Anna Skwarska, Karolina Chwialkowska, Agnieszka Ostrowska, Gabriela Sokolowska, Anna Zeller, Anna Erol, Andrzej Eljaszewicz, Bartosz Hanczaruk, Anna Michalska‐Falkowska, Agnieszka Tarasik, Joanna Reszec‐Gielazyn, Pawel Knapp, Marcin Moniuszko, Adam Kretowski   +14 more
wiley   +1 more source

Melatonin Does Not Alter Cell Proliferation in Metastatic Breast Cancer Cells

Proceedings, 2018
Breast cancer treatments continue to be investigated with supported by new treatment methods. Melatonin is a hormone that can be effective in the treatment of breast cancer due to its anti-oxidant effect.
Gamze Tanriover, Sayra Dilmac, Nuray Erin   +2 more
doaj   +1 more source

Combining mammaglobin and carcinoembryonic mRNA markers for early detection of micrometastases from breast cancers - a molecular study of 59 patients [PDF]

, 2006
Introduction: As many as 30% of node-negative breast cancer patients relapse within five years, suggesting that current histological detection methods are inadequate for identifying metastatic disease. Detecting small number of cancer cells in the breast
Dastan, J., Ghaffari, S.R., Mohagheghi, M.A., Moradi, A., Mosavi-Jarrahi, A., Sabokbar, T., Shorakae, S., Tahmasebi, S., Tirgari, F.   +8 more
core  

Integrated genomic and proteomic profiling reveals insights into chemoradiation resistance in cervical cancer

Molecular Oncology, EarlyView.
A comprehensive genomic and proteomic analysis of cervical cancer revealed STK11 and STX3 as a potential biomarkers of chemoradiation resistance. Our study demonstrated EGFR as a therapeutic target, paving the way for precision strategies to overcome treatment failure and the DNA repair pathway as a critical mechanism of resistance.
Janani Sambath, Irene A. George, Srikanth S. Manda, Prasanth Ariyannur, Ekta R. Dhawale, Raja Sekhar Kommu, Rajan Datar, Darshana Patil, Vinita Trivedi, Manisha Singh, Kumar Prabhash, Sewanti Limaye, Richa Chauhan, Prashant Kumar   +13 more
wiley   +1 more source

Metastatic Breast Cancer and Hormonal Receptor Status among a Group of Women in Sub Saharan Africa

The Annals of African Surgery, 2018
Background: Breast cancer is the third commonest cancer in women in Uganda. The majority of breast cancer patients in Uganda present with advanced disease. Many studies show that metastatic lesions frequently lodge in bones, lung and liver.
Nabawanuka A, Galukande M, Nalwoga H, Gakwaya A   +3 more
doaj